These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10087967

  • 21. Combined therapy with Fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas.
    Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M.
    Eur J Haematol; 1997 Nov; 59(5):327-8. PubMed ID: 9414645
    [No Abstract] [Full Text] [Related]

  • 22. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
    Roberts JD, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S.
    Clin Cancer Res; 2006 Oct 01; 12(19):5809-16. PubMed ID: 17020988
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH, de Takats PG, Kraus C, Klein M, Lister TA.
    J Clin Oncol; 1999 May 01; 17(5):1574-9. PubMed ID: 10334546
    [Abstract] [Full Text] [Related]

  • 24. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
    Pawelski S.
    Acta Haematol Pol; 1995 May 01; 26(3):263-8. PubMed ID: 8525771
    [Abstract] [Full Text] [Related]

  • 25. [Use of fludarabin in conjunction with other cytostatics in the treatment of non-Hodgkin lymphoma resistant to standard chemotherapy].
    Gershanovich ML, Tikhonova VV.
    Vopr Onkol; 2004 May 01; 50(5):602-4. PubMed ID: 15715106
    [Abstract] [Full Text] [Related]

  • 26. Fludarabine: a review of its use in non-Hodgkin's lymphoma.
    Anderson VR, Perry CM.
    Drugs; 2007 May 01; 67(11):1633-55. PubMed ID: 17661532
    [Abstract] [Full Text] [Related]

  • 27. [Phase II clinical study of SH L 573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia].
    Miyawaki S, Imamura M, Kobayashi S, Ohnishi K, Hodohara K, Mizoguchi H, Tomonaga M, Tango T, Ohno R.
    Rinsho Ketsueki; 1999 Dec 01; 40(12):1236-44. PubMed ID: 10658476
    [Abstract] [Full Text] [Related]

  • 28. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
    Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T.
    J Clin Oncol; 2006 Jan 01; 24(1):174-80. PubMed ID: 16330664
    [Abstract] [Full Text] [Related]

  • 29. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Boogaerts MA, Van Hoof A, Catovsky D, Kovacs M, Montillo M, Zinzani PL, Binet JL, Feremans W, Marcus R, Bosch F, Verhoef G, Klein M.
    J Clin Oncol; 2001 Nov 15; 19(22):4252-8. PubMed ID: 11709569
    [Abstract] [Full Text] [Related]

  • 30. Fludarabine therapy in chronic lymphocytic leukemia (CLL).
    Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB.
    Nouv Rev Fr Hematol (1978); 1988 Nov 15; 30(5-6):461-6. PubMed ID: 2464794
    [Abstract] [Full Text] [Related]

  • 31. A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Willis CR, Goodrich A, Park K, Waselenko JK, Lucas M, Reese A, Diehl LF, Grever MR, Byrd JC, Flinn IW.
    Ann Hematol; 2006 May 15; 85(5):301-7. PubMed ID: 16518606
    [Abstract] [Full Text] [Related]

  • 32. Fludarabine phosphate in lymphoma: an important new therapeutic agent.
    McLaughlin P, Robertson LE, Keating MJ.
    Cancer Treat Res; 1996 May 15; 85():3-14. PubMed ID: 9043771
    [No Abstract] [Full Text] [Related]

  • 33. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
    Alas S, Bonavida B, Emmanouilides C.
    Anticancer Res; 2000 May 15; 20(5A):2961-6. PubMed ID: 11062708
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma.
    Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ.
    J Clin Oncol; 1992 May 15; 10(5):790-4. PubMed ID: 1373760
    [Abstract] [Full Text] [Related]

  • 38. Fludarabine phosphate for the treatment of low grade lymphoid malignancy.
    Whelan JS, Davis CL, Rule S, Ranson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZ, Lister TA.
    Br J Cancer; 1991 Jul 15; 64(1):120-3. PubMed ID: 1713049
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.
    Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB.
    J Clin Oncol; 1991 Jan 15; 9(1):44-9. PubMed ID: 1702145
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.